© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
First-Ever Long COVID Tissue Bank Launched at University of California San Francisco
February 27, 2024
"Viral reservoirs" in human tissue may preserve the SARS-CoV-2 virus, provoking an immune response that could drive long COVID-associated symptoms.
Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA
February 26, 2024
neffy (epinephrine nasal spray) delivered a PK and PD profile greater than or similar to that of IM epinephrine after extreme nasal challenge, reports ARS Pharmaceuticals.
SCIT May Augment Treatment for EoE with Comorbid Allergic Rhinitis: New Observations
February 23, 2024
The largest study of the differential impact of subcutaneous immunotherapy on people with EoE and allergic rhinitis found no worsening of EoE and that it could be "helpful."
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
February 23, 2024
AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.
FDA Accepts Dupilumab sBLA for Priority Review for Treatment of COPD with Type 2 Inflammation
February 23, 2024
A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.
New neffy Data on Clinical Efficacy Presented at 2024 AAAAI Annual Meeting
February 22, 2024
AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study
February 21, 2024
AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.
First Study of Oral Mucosal Immunotherapy for Peanut Allergy Elicits Robust Immunologic Response in Adults
February 21, 2024
AAAAI 2024. Oral mucosal immunotherapy delivered via metered-dose toothpaste produced a statistically significant increase in IgG4 and a decrease in IgE/IgG4 ratio.
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers
February 21, 2024
AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.
Women with IBD at Risk for Reduced Fertility Even During Clinical Disease Remission, Study Suggests
February 20, 2024
Histologic inflammation was associated with reduced fertility whether IBD disease was active or quiescent in a nationwide study of Swedish women aged 15 to 44 years.